ESMO expert consensus statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancer
Year: 2023
Type: article
Source: Annals of Oncology
Authors: P. Tarantino, G. Viale, M.F. Press, X. Hu, F. Penault-Llorca, A. Bardia, A. Batistatou, H.J. Burstein, L.A. Carey, J. Cortes, C. Denkert, V. Diéras, W. Jacot, A.K. Koutras, A. Lebeau, S. Loibl, S. Modi, M.F. Mosele, E. Provenzano, G. Pruneri, J.S. Reis-Filho, F. Rojo, R. Salgado, P. Schmid, S.J. Schnitt, S.M. Tolaney, D. Trapani, A. Vincent-Salomon, A.C. Wolff, G. Pentheroudakis, F. André, G. Curigliano
Institutions: Harvard University, University of Milan, Dana-Farber Cancer Institute, Dana-Farber/Harvard Cancer Center, European Institute of Oncology, University of Southern California, USC Norris Comprehensive Cancer Center, Fudan University, Fudan University Shanghai Cancer Center, Centre Jean Perrin, Massachusetts General Hospital, University of Ioannina, University of North Carolina at Chapel Hill, UNC Lineberger Comprehensive Cancer Center, IDCQ Hospitales y Sanidad, S.L.U., Universidad Europea de Madrid, Philipps University of Marburg, Universitätsklinikum Gießen und Marburg, Centre Eugène Marquis, Inserm, Institut de Recherche en Cancérologie de Montpellier, General University Hospital of Patras, University Medical Center Hamburg-Eppendorf, Goethe University Frankfurt, German Breast Group, Memorial Sloan Kettering Cancer Center, Institut Gustave Roussy, University of Cambridge, NIHR Cambridge Biomedical Research Centre, Fondazione IRCCS Istituto Nazionale dei Tumori, Hospital Universitario Fundación Jiménez Díaz, Centro de Investigación Biomédica en Red de Cáncer, Peter MacCallum Cancer Centre, Ziekenhuis aan de Stroom, Peter MacCallum Cancer Foundation, Queen Mary University of London, Barts Cancer Institute, Brigham and Women's Hospital, Dana-Farber Brigham Cancer Center, Université Paris Sciences et Lettres, Institut Curie, Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, European Society for Medical Oncology
Language: English
Topic: HER2/EGFR in Cancer Research
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
Funders: Breast Cancer Research Foundation, Eli Lilly and Company, Pfizer, AstraZeneca, Roche, Sanofi, Gilead Sciences, Dr. Miriam and Sheldon G. Adelson Medical Research Foundation, Ariad Pharmaceuticals, Celgene, Queen Mary University of London, Baxalta, Les Laboratories Pierre Fabre, Radius Health, Mersana Therapeutics, Veracyte, Seagen, Bayer HealthCare, Eisai, Astellas Pharma, European Society for Medical Oncology, Servier, Genentech, Samsung, Takeda Oncology, Foundation Medicine, Daiichi Sankyo Europe
OpenAlex ID: W4378978327